NC Testing in LC & POTS

Neurocognitive Testing in Long COVID and Postural Tachycardia Syndrome Patients With Normal Saline: A Pilot Study

Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Post-Acute Sequelae of COVID (PASC, or "Long COVID") experience cognitive dysfunction. The investigators will test the hypothesis that 1500mL of IV saline will improve cognitive function in patients with POTS and Long COVID, compared to placebo (50mL of saline).

Study Overview

• Status: Not yet recruiting
• Conditions: Postural Orthostatic Tachycardia Syndrome; Post Acute Sequelae of SARS CoV 2 Infection
• Intervention / Treatment: Other: IV normal saline (1500mL infusion); Other: IV normal saline (50mL infusion)

Detailed Description

Many POTS patients report cognitive dysfunction, otherwise referred to as brain fog, mental fog, mental clouding, or mental fatigue. Importantly, this cognitive dysfunction can occur even while lying down or seated, limiting ability to engage in work and educational activities. Despite the prevalence and clinical impact of cognitive dysfunction in POTS, there are limited studies examining this phenomenon. Many patients with post acute sequelae of SARS- COV-2 (PASC, or "Long COVID") experience symptoms such as subjective cognitive impairment, ("brain fog"), fatigue, memory loss, headache, and fluctuation of blood pressure amongst other signs and symptoms. This study will measure cognitive function in patients with POTS and Long COVID, compared to healthy controls. This study will also evaluate IV normal saline (1500mL infusion) as a potential treatment for reduced cognitive function in POTS and Long COVID. A 50mL saline infusion will be used as a placebo control in this cross-over study.

The findings from this study will be an initial first step towards understanding any neurocognitive impairment in participants with long COVID and POTS patients. This is a critical first step to future studies to assess underlying pathophysiology and potential treatments.

Primary hypothesis: Some objective measures of neurocognitive functions will improve in Long COVID and POTS patients after the infusion of 1500mL of normal saline compared to 50mL placebo control.

The primary analysis will compare the standing 5RTI task on the CANTAB testing scores between 1500mL saline infusion and 50mL saline infusion (placebo).

Study Day and Instrumentation:

• A trained research staff member will insert an intravenous line in the vein of the participant arm to give either 1500 ml or 50 ml of normal saline which can take up to 30 minutes. Normal saline will be administered by a trained research staff member.
• After instrumentation, participant will lie supine for at least 10 minutes while their ECG & BP are continuously recorded.
• The participant will stand up quickly (within several seconds), and then stand quietly for about 11 minutes while recording continues. The lying-> stand will allow us to assess for hemodynamics of IST, POTS & OH. Any time during the test, they want to sit down a chair will be provided to them.
• After the stand test, participant will be asked to do the Trail Making Test (TMT) in the standing position. They will be asked to join numbers and letters in a circle. This test should not take more than approximately 10 minutes. Any time during the test, they want to sit down a chair will be provided to them.
• The participant will then be seated comfortably in a chair with their feet on the floor. They will be asked to do the Heart Counting Task (HCT) test. The participant will be asked to count their heartbeats without using their hands or other means to feel pulse that might affect their performance. This test will approximately take around 10 minutes.
• The research team will then de instrument the participant except for the Blood Pressure cuff on the arm. The research team will continue to monitor the blood pressure throughout the study.
• Neuropsychological testing of the cognitive domains of memory, attention and executive function will be assessed using the Cambridge Neuropsychological Test Automated Battery (CANTAB) both seated and standing. .
• The seated cognitive testing period will last approximately 60 minutes.
• The participant will be asked to stand unaided for up to 30 minutes and repeat portions of the CANTAB tests. Blood Pressure will be monitored throughout the stand test. A chair will be provided to the participant in case they would want to sit down.
• At the end of each stand test, the investigators will assess patient symptoms using the Vanderbilt Orthostatic Symptoms Score (VOSS). VOSS is a 9-item symptom-rating with each item score from 0-10 (worst) for a total score ranging from 0-90.
• The study will then be finished. The investigators will remove the recording patches and electrodes.
• The participant will then be booked for the second visit according to their convenience where all the tests will be repeated, including: IV insertion & infusion of normal saline, supine, stand, and the cognitive tests (CANTAB, TMT & HCT). Repeating these tests will help the research team in assessing if, the cognitive functions will improve for the Long COVID and POTS patients with blood volume expansion with the infusion of normal saline.

CANTAB Testing Protocol: CANTAB tests have demonstrated sensitivity to detecting changes in neuropsychological performance and include tests of working memory, learning and executive function; visual, verbal and episodic memory; attention, information processing and reaction time; social and emotion recognition, decision making and response control. The subtests that will be used in this study for seated cognitive function are: Reaction Time Test (psychomotor Speed), Rapid Visual Information processing (Attention), Paired Associates Learning (Visual Episodic Memory), Spatial Span (Working memory), Verbal Recognition Memory (Verbal memory), Multitasking Test (Executive Function - Inhibition), Stocking of Cambridge (Executive Function - Planning) and the Emotional Bias Task (Emotion Processing). All tests are administered using a touch screen tablet, participants will respond to each test on-screen. Standardized written and audio instructions are given to participants through the software, and practice trials are completed before each test, reducing practice effects. Seated testing will be completed in approximately 60 minutes. The Reaction Time Test, Rapid Visual Processing and the Multi Tasking tests will be repeated upon standing and will take approximately 30 minutes to complete.

After the in-lab portion of the study, participants will complete a series of validated questionnaires through a paper or RedCap secure web application for assessment of psychiatric symptoms. A unique URL link will be sent to the participants via Redcap Survey. These online surveys will take ~60 minutes to complete.

• Study Type: Interventional
• Enrollment (Estimated): 50
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Satish R Raj, MD MSCI; Phone Number: 4032106152; Email: autonomic.research@ucalgary.ca
• Study Contact Backup: Name: Tanya Siddiqui, MBBS; Email: autonomic.research@ucalgary.ca

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Patients with diagnosis of Long COVID
• SARS-COV2 test positive
• Symptoms > 12 weeks post COVID
• Subjective complaint of 'brain fog" or cognitive dysfunction
• Patients with diagnosis of Postural Orthostatic Syndrome (POTS) from the Calgary Autonomic Investigation and Management Clinic
• Subjective complaint of 'brain fog" or cognitive impairment
• Healthy participants
• Without POTS or "brain fog"
• Age 18 to 60 years
• Female and Male
• Able to give an informed consent

Exclusion Criteria:

• Patients with overt causes for POTS (e.g., dehydration, prolonged bed rest)
• An inability to safely withdraw from medicine(s) that could make test interpretation difficult and impossible.
• Other factors which are in the investigator's opinion would prevent the participant from completing the protocol, including poor compliance during previous studies or an unpredictable schedule.
• Unable to give an informed consent.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 1500mL Normal Saline; 1500mL of normal saline infused intravenously.	Other: IV normal saline (1500mL infusion); 1500mL of IV normal saline will be infused intravenously
Placebo Comparator: 50mL Normal Saline; 50mL of normal saline infused intravenously.	Other: IV normal saline (50mL infusion); 50mL of IV normal saline will be infused intravenously as a placebo control.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
5RTI Reaction Time task (Standing)	5RTI Reaction Time Score (Standing) after 1500mL IV saline compared to 5RTI score after 50mL IV saline measured in milliseconds (ms). The minimum score is 100 ms and the maximum score is 5100 ms. A longer time is a worse outcome.	During Procedure (3 hours)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Reaction Time Test (Psychomotor Speed)	Reaction Time Test score after 1500mL IV saline compared to after 50mL IV saline measured in milliseconds. The minimum score is 100 ms and the maximum score is 5100 ms. A longer time is a worse outcome.	During Procedure (3 hours)
Paired Associates Learning (Visual Episodic Memory)	Paired Associates Learning score after 1500mL IV saline compared to after 50mL IV saline measured in arbitrary units. The minimum score is 0 and the maximum score is 70. A higher score is a worse outcome.	During Procedure (3 hours)
Verbal Recognition Memory (Verbal memory)	Verbal Recognition Memory test score after 1500mL IV saline compared to after 50mL IV saline. The range is 0-18. A higher score is a better outcome.	During Procedure (3 hours)
Multitasking Test (Executive Function - Inhibition)	Multitasking Test Time after 1500mL IV saline compared to after 50mL IV saline measured in ms. The range is 100 - 2000 ms. A longer time is a worse is a worse outcome.	During Procedure (3 hours)

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Sitting heart rate	Sitting heart rate after 1500mL IV saline compared to after 50mL IV saline.	During Procedure (10 minutes)
Standing heart rate	Standing heart rate after 1500mL IV saline compared to after 50mL IV saline.	During Procedure (10 minutes)

Collaborators and Investigators

• Sponsor: University of Calgary

Study record dates

Study Major Dates

• Study Start (Estimated): November 1, 2023
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2027

Study Registration Dates

• First Submitted: June 13, 2023
• First Submitted That Met QC Criteria: June 13, 2023
• First Posted (Actual): June 22, 2023

Study Record Updates

• Last Update Posted (Actual): October 13, 2023
• Last Update Submitted That Met QC Criteria: October 11, 2023
• Last Verified: June 1, 2023

More Information

Terms related to this study

• Keywords: Long COVID; POTS; Cognitive
• Additional Relevant MeSH Terms: Pathologic Processes; Heart Diseases; Cardiovascular Diseases; Nervous System Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; Disease Attributes; Disease; Arrhythmias, Cardiac; Cardiac Conduction System Disease; Autonomic Nervous System Diseases; Primary Dysautonomias; Orthostatic Intolerance; Chronic Disease; Post-Infectious Disorders; COVID-19; Syndrome; Tachycardia; Postural Orthostatic Tachycardia Syndrome; Post-Acute COVID-19 Syndrome
• Other Study ID Numbers: REB23-0202

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No